Immunome, Inc. Research and Development Expense
Immunome, Inc. (IMNM) reported Research and Development Expense of $59.88 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:ResearchAndDevelopmentExpense · last filed 2026-08-11
- Immunome, Inc. research and development expense for the quarter ending 2026-06-30 was $59.88M, a 48.04% increase year-over-year.
- Immunome, Inc. research and development expense for the quarter ending 2026-03-31 was $46.38M, a 25.79% increase year-over-year.
- Immunome, Inc. research and development expense for the quarter ending 2025-12-31 was $50.77M, a 6.01% increase year-over-year.
- Immunome, Inc. research and development expense for the quarter ending 2025-09-30 was $49.19M, a 32.24% increase year-over-year.
- Immunome, Inc. research and development expense for fiscal 2025 was $177.29M, a 36.86% increase from fiscal 2024.
- Immunome, Inc. research and development expense for fiscal 2024 was $129.54M, a 461.06% increase from fiscal 2023.
- Immunome, Inc. research and development expense for fiscal 2023 was $23.09M, a 0.79% decline from fiscal 2022.
- Immunome, Inc. research and development expense for fiscal 2022 was $23.27M, a 64.93% increase from fiscal 2021.
| Period end | Research and Development Expense 3 month | Research and Development Expense 6 month | Research and Development Expense 9 month | Research and Development Expense 12 month |
|---|---|---|---|---|
| 2026-06-30 | $59.88M 10-Q · filed 2026-08-11 | $106.27M 10-Q · filed 2026-08-11 | $157.04M derived: sum of 3 quarters · filed 2026-08-11 | $206.23M derived: sum of 4 quarters · filed 2026-08-11 |
| 2026-03-31 | $46.38M 10-Q · filed 2026-05-12 | $97.15M derived: sum of 2 quarters · filed 2026-05-12 | $146.34M derived: sum of 3 quarters · filed 2026-05-12 | $186.79M derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-12-31 | $50.77M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-03 | $99.96M derived: sum of 2 quarters · filed 2026-03-03 | $140.41M derived: sum of 3 quarters · filed 2026-08-11 | $177.29M 10-K · filed 2026-03-03 |
| 2025-09-30 | $49.19M 10-Q · filed 2025-11-06 | $89.64M derived: sum of 2 quarters · filed 2026-08-11 | $126.52M 10-Q · filed 2025-11-06 | $174.41M derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-06-30 | $40.45M 10-Q · filed 2026-08-11 | $77.32M 10-Q · filed 2026-08-11 | $125.21M derived: sum of 3 quarters · filed 2026-08-11 | $162.41M derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-03-31 | $36.87M 10-Q · filed 2026-05-12 | $84.76M derived: sum of 2 quarters · filed 2026-05-12 | $121.96M derived: sum of 3 quarters · filed 2026-05-12 | $151.04M derived: sum of 4 quarters · filed 2026-05-12 |
| 2024-12-31 | $47.89M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-03 | $85.09M derived: sum of 2 quarters · filed 2026-03-03 | $114.17M derived: sum of 3 quarters · filed 2026-03-03 | $129.54M 10-K · filed 2026-03-03 |
| 2024-09-30 | $37.20M 10-Q · filed 2025-11-06 | $66.28M derived: sum of 2 quarters · filed 2025-11-06 | $81.65M 10-Q · filed 2025-11-06 | $91.29M derived: sum of 4 quarters · filed 2025-11-06 |
| 2024-06-30 | $29.08M 10-Q · filed 2025-08-06 | $44.45M 10-Q · filed 2025-08-06 | $54.09M derived: sum of 3 quarters · filed 2025-08-06 | $57.91M derived: sum of 4 quarters · filed 2025-08-06 |
| 2024-03-31 | $15.37M 10-Q · filed 2025-05-12 | $25.01M derived: sum of 2 quarters · filed 2025-05-12 | $28.83M derived: sum of 3 quarters · filed 2025-05-12 | $34.55M derived: sum of 4 quarters · filed 2025-05-12 |
| 2023-12-31 | $9.64M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-19 | $13.46M derived: sum of 2 quarters · filed 2025-03-19 | $19.18M derived: sum of 3 quarters · filed 2025-03-19 | $23.09M 10-K · filed 2025-03-19 |
| 2023-09-30 | $3.82M 10-Q · filed 2024-11-13 | $9.54M derived: sum of 2 quarters · filed 2024-11-13 | $13.45M 10-Q · filed 2024-11-13 | $17.70M derived: sum of 4 quarters · filed 2024-11-13 |
| 2023-06-30 | $5.72M 10-Q · filed 2024-08-12 | $9.63M 10-Q · filed 2024-08-12 | $13.88M derived: sum of 3 quarters · filed 2024-08-12 | $19.11M derived: sum of 4 quarters · filed 2024-08-12 |
| 2023-03-31 | $3.91M 10-Q · filed 2024-05-14 | $8.16M derived: sum of 2 quarters · filed 2024-05-14 | $13.39M derived: sum of 3 quarters · filed 2024-05-14 | $19.11M derived: sum of 4 quarters · filed 2024-05-14 |
| 2022-12-31 | $4.25M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-28 | $9.48M derived: sum of 2 quarters · filed 2024-03-28 | $15.19M derived: sum of 3 quarters · filed 2024-03-28 | $23.27M 10-K · filed 2024-03-28 |
| 2022-09-30 | $5.22M 10-Q · filed 2023-11-09 | $10.94M derived: sum of 2 quarters · filed 2023-11-09 | $19.02M 10-Q · filed 2023-11-09 | $23.41M derived: sum of 4 quarters · filed 2023-11-09 |
| 2022-06-30 | $5.72M 10-Q · filed 2023-08-09 | $13.79M 10-Q · filed 2023-08-09 | $18.18M derived: sum of 3 quarters · filed 2023-08-09 | $22.69M derived: sum of 4 quarters · filed 2023-08-09 |
| 2022-03-31 | $8.08M 10-Q · filed 2023-05-05 | $12.46M derived: sum of 2 quarters · filed 2023-05-05 | $16.98M derived: sum of 3 quarters · filed 2023-05-05 | $20.21M derived: sum of 4 quarters · filed 2023-05-05 |
| 2021-12-31 | $4.38M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-16 | $8.90M derived: sum of 2 quarters · filed 2023-03-16 | $12.13M derived: sum of 3 quarters · filed 2023-03-16 | $14.11M 10-K · filed 2023-03-16 |
| 2021-09-30 | $4.51M 10-Q · filed 2022-11-14 | $7.75M derived: sum of 2 quarters · filed 2022-11-14 | $9.72M 10-Q · filed 2022-11-14 | $11.56M derived: sum of 4 quarters · filed 2022-11-14 |
| 2021-06-30 | $3.23M 10-Q · filed 2022-08-05 | $5.21M 10-Q · filed 2022-08-05 | $7.05M derived: sum of 3 quarters · filed 2022-08-05 | $8.69M derived: sum of 4 quarters · filed 2022-08-05 |
| 2021-03-31 | $1.98M 10-Q · filed 2022-05-12 | $3.81M derived: sum of 2 quarters · filed 2022-05-12 | $5.46M derived: sum of 3 quarters · filed 2022-05-12 | $7.35M derived: sum of 4 quarters · filed 2022-05-12 |
| 2020-12-31 | $1.83M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-28 | $3.48M derived: sum of 2 quarters · filed 2022-03-28 | $5.37M derived: sum of 3 quarters · filed 2022-03-28 | $7.49M 10-K · filed 2022-03-28 |
| 2020-09-30 | $1.64M 10-Q · filed 2021-11-15 | $3.54M derived: sum of 2 quarters · filed 2021-11-15 | $5.65M 10-Q · filed 2021-11-15 | $8.08M derived: sum of 4 quarters · filed 2021-11-15 |
| 2020-06-30 | $1.89M 10-Q · filed 2021-08-16 | $4.01M 10-Q · filed 2021-08-16 | $6.44M derived: sum of 3 quarters · filed 2021-08-16 | $8.67M derived: sum of 4 quarters · filed 2021-08-16 |
| 2020-03-31 | $2.12M 10-Q · filed 2021-05-12 | $4.55M derived: sum of 2 quarters · filed 2021-05-12 | $6.78M derived: sum of 3 quarters · filed 2021-05-12 | |
| 2019-12-31 | $2.43M derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-25 | $4.67M derived: sum of 2 quarters · filed 2021-03-25 | $8.82M 10-K · filed 2021-03-25 | |
| 2019-09-30 | $2.23M 10-Q · filed 2020-11-16 | $6.39M 10-Q · filed 2020-11-16 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Disc Medicine, Inc. (IRON) | United States | $2.553B | -11.40 |
| SUPERNUS PHARMACEUTICALS, INC. (SUPN) | United States | $2.517B | -24.63 |
| Nurix Therapeutics, Inc. (NRIX) | United States | $2.457B | -5.39 |
| SELLAS Life Sciences Group, Inc. (SLS) | United States | $2.420B | -91.87 |
| uniQure N.V. (QURE) | $2.416B | -4.93 | |
| MBX Biosciences, Inc. (MBX) | United States | $2.664B | -25.36 |
| Vera Therapeutics, Inc. (VERA) | United States | $2.402B | -7.67 |
| Harmony Biosciences Holdings, Inc. (HRMY) | United States | $2.399B | 11.67 |
| NewAmsterdam Pharma Co N.V. (NAMS) | $2.719B | -15.37 | |
| Mineralys Therapeutics, Inc. (MLYS) | United States | $2.353B | -6.82 |